Skeletal dysplasias are difficult to diagnose for the nonexpert. In a previous study of patients with multiple epiphyseal dysplasia (MED), we identified cartilage oligomeric matrix protein (COMP) mutations in only 36% of cases and suspected that the low-mutation detection rate was partially due to misdiagnosis. We therefore instituted a clinical -radiographic review system, whereby all cases were evaluated by a panel of skeletal dysplasia experts (European Skeletal Dysplasia Network). Only those patients in whom the diagnosis of MED was confirmed by the panel were screened for mutations. Under this regimen the mutation detection rate increased to 81%. When clinical-radiological diagnostic criteria were relaxed the mutation rate dropped to 67%. We conclude that expert clinical -radiological review can significantly enhance mutation detection rates and should be part of any diagnostic mutation screening protocol for skeletal dysplasias.
Introduction
Multiple epiphyseal dysplasia (MED) is a skeletal dysplasia characterized by delayed and irregular ossification of the epiphyses and early-onset osteoarthritis. Patients typically present with joint pain and stiffness particularly in the hips and knees and may have mild short stature.
MED can result from mutations in the genes encoding cartilage oligomeric matrix protein (COMP), type IX collagen (COL9A1, COL9A2 and COL9A3), matrilin-3 (MATN3) and the diastrophic dysplasia sulphate transporter (DTDST) (SLC26A2). 1, 2 The frequency of mutations in these genes is not well established but previous studies have suggested detection rates of 10 -28% for COMP, 3, 4 14% for DTDST, 4 10% for MATN3 and 5 -10% for the type IX collagen genes. 1, 4 In a recent study of 58 families with MED, we identified COMP mutations in 36% (21/58) of patients. 5 These patients were diagnosed by their referring physician, mostly clinical geneticists. Even though some of the cases might have been caused by mutations in the other genes associated with MED, we suspected that misdiagnosis contributed to the low COMP mutation detection rate. We therefore tested the hypothesis that the preselection of cases, through expert clinical and radiological review, could significantly increase the mutation detection rate in MED.
Methods
During Mutation screening of the COMP, COL9A1, COL9A2, COL9A3, MATN3 and DTDST genes was performed as described previously. 5 -7 Briefly, polymerase chain reaction (PCR) amplification of exons 8 -19, including the immediate splice donor and acceptor sites of the COMP gene was performed using exon-specific intronic primers in eight separate PCR amplicons. PCR amplification of exon 2 of MATN3 was performed as a single reaction. Purified PCR products were used as a template for bi-directional fluorescent DNA sequencing and the DNA sequence data was compared against a reference sequence to detect variants using the Staden sequence analysis package. 8 All DNA sequence traces were compared with a normal nonaffected control and also checked against the published cDNA sequences. One patient was diagnosed with a type II collagenopathy by the expert panel (see Results) and mutation screening of the COL2A1 was performed.
Results
Of the 35 patients referred to ESDN, 24 were diagnosed with 'classical' MED by the expert panel and five cases were considered possible MED variants (see Figures 1 and 2 for representative examples). Two patients were diagnosed with a type II collagenopathy and spondyloepimetaphyseal dysplasia (SEMD) with multiple dislocations (type Hall or leptodactylic type), respectively. No diagnosis could be made in four patients and these were classified as 'unknown'. Genomic DNA for mutation analysis of the known 'MED-disease' genes could be obtained from 21 of the 29 eligible patients. Mutations were identified in 13 of the 16 patients with classical MED and in one of the five patients classified as possible MED variants. Of the 14 mutations identified, 13 were located in the COMP and one in the Three cases were considered to have typical features of MED but no mutation could be identified ( Table 2 ). The radiographs and available clinical information of these cases are given in Figures 3 -5 . Illustrates the mutation detection rate in relation to the clinical diagnosis. In 81% of patients (13/16) diagnosed with classic MED, a mutation in one of the 'MED-disease' genes was identified. In those patients with an atypical clinical -radiological presentation, the mutation detection rate was only 20% (1/5). The overall mutation detection rate, considering both classical and atypical presentations, was therefore 67% (14/21). Clinical and molecular diagnosis A Zankl et al
Discussion
By employing a clinical and radiographic review protocol, in which all referred MED cases were evaluated by a panel of skeletal dysplasia experts, we were able to increase the mutation detection rate to 81%. These findings indicate that mutations in the six known MED-disease genes are responsible for the vast majority of MED cases, and lower detection rates in previous studies are probably the result of misdiagnosis. Itoh et al 10 recently reported a high mutation detection rate of 54% when screening patients with MED for mutations in the six known MED genes. 10 These patients were recruited through specialized skeletal dysplasia clinics, which might have contributed to the high mutation detection rate. In our study, rigorous clinicalradiological preselection through a panel of experts resulted in an even higher mutation detection rate. The lack of an identifiable mutation in 19% of cases with the typical clinical -radiological features of MED suggests that a small, but significant, proportion of MED cases are caused by mutation in an as yet unknown gene. It should be noted that our mutation screening strategy does not allow us to detect single exon deletions, more complex deletions or mutations in intronic splicing elements outside of the immediate splice donor and acceptor sequences. There remains therefore the remote possibility that mutations of this type could account for the phenotype in these cases.
Most mutations identified in this study were located in the COMP gene verifying that it is the major genetic locus for MED and suggesting that mutations in matrilin-3 and type IX collagen are responsible for only a small proportion of autosomal dominant MED cases. To date, all recessive forms of MED (rMED: EDM4) can be ascribed to mutations in SLC26A2, but this does not exclude the possibility that mutations in other genes can also account for rMED.
The relaxation of diagnostic criteria to allow for the existence of possible MED variants significantly decreased the mutation detection rate. In only one of five cases with an atypical presentation was a mutation identified (20%). These findings indicate that the MED phenotype is relatively well defined and that while the identification of rare MED variants is important from an academic point of view, strict diagnostic criteria should be applied in a routine diagnostic setting to allow for an efficient screening protocol.
In addition to improving the mutation detection rate and thus making genetic testing for MED more efficient, Clinical and molecular diagnosis A Zankl et al expert clinical -radiographic review allowed the revision of the diagnosis in two cases. One case was diagnosed with a type II collagenopathy, and a mutation in COL2A1 was subsequently identified. No molecular testing is available to confirm the revised diagnosis of SEMD (type Hall or leptodactylic type) in the second case, but the consensus of several experts makes this diagnosis very likely. Both cases would have remained undiagnosed without expert clinical -radiological review before genetic testing.
In summary, we conclude that expert clinical and radiological review can improve diagnostic accuracy and significantly enhance mutation detection rates. Review and preselection should be part of any diagnostic mutation screening protocol for patients with skeletal dysplasias or any other rare genetic disease that requires expert knowledge for diagnosis. Furthermore, our data confirm that COMP is the major genetic locus for autosomal dominant forms of MED.
